UBS Maintains Buy on Biogen, Raises Price Target to $240

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $240.

Comments

No comments yet. Be the first!